Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001032719 | SCV001196026 | pathogenic | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | 2019-11-18 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exon 1 of the HMGCS2 gene, which includes the initiator codon. The 5' end of this event is unknown as it extends beyond the assayed region for this gene and therefore may encompass additional genes. The 3' boundary is likely confined to intron 1 of the HMGCS2 gene. This is expected to result in an absent or disrupted protein product. This variant has been observed in individual(s) with clinical features of HMG-CoA synthase-2 deficiency (Invitae). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. Loss-of-function variants in HMGCS2 are known to be pathogenic (PMID: 20346956, 23751782, 25511235). For these reasons, this variant has been classified as Pathogenic. |